Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Summary

The purpose of this early (phase I/II) clinical trial is to assess the effects (both good and bad) of genetically modified T cells after chemotherapy on your cancer and general health.

Timeline

Start

2011-06-01

Primary completion

2016-02-17

Completion

2018-03-01

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of enrollment”

Drugs

Indications